2019 Drug Safety Communications
Current Drug Safety Communications More Drug Safety Communications
- 12-19-2019: FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)
- 9-13-2019: FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verz2019:enio for breast cancer
- 8-28-2019: FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease
- 8-13-2019: FDA review finds no increased risk of prostate cancer with Parkinson's disease medicines containing entacapone (Comtan, Stalevo)
- 7-26-2019: FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)
- 4-30-2019: FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines
- 4-9-2019: FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering
- 2-25-2019: Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate
- 2-21-2019: FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)